Pregnant individuals are advised to receive the RSV vaccine between 32 and 36 weeks of pregnancy, with a recommended window from September to January, although RSV can persist until mid-May. Older ...

The following is a summary of “RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing,” published in the ...

A preventative medication against the respiratory syncytial virus (RSV) will be available for newborns in Austria before ...

Infant deaths during a trial of a medicine that protects against respiratory syncytial virus were caused by unrelated factors ...

AstraZeneca introduced two new products, palivizumab and tremelimumab injections, into the Indian market, receiving ...

Get detailed information on Palivizumab, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

Although 1 in 4 hospitalizations was due to an RSV infection, all the children with SMA given seasonal RSV-preventive treatment with palivizumab avoided being hospitalized. Palivizumab is sold as ...

Interim findings show clesrovimab has a similar safety profile to palivizumab. Clesrovimab, an investigational respiratory syncytial virus (RSV) fusion glycoprotein neutralizing monoclonal antibody, ...

Merck (NYSE:MRK) also announced interim data from a Phase 3 trial testing clesrovimab against RSV therapy palivizumab in infants and children at a higher risk for severe RSV disease. As for the ...

Merck also announced data from a planned interim analysis of the MK-1654-007 trial, a Phase 3 trial evaluating the safety and efficacy of clesrovimab versus palivizumab in infants and children at ...

Nirsevimab, the RSV monoclonal antibody, is preferred over palivizumab and the RSVpreF (Abrysvo TM) vaccine. Nirsevimab should be prioritized for infants: 75 years of age and older, particularly for ...

AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...